VBI Vaccines Acquires Epixis To Expand Immunotherapy Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
The purchase of its French partner gives VBI a virus-like particle discovery platform to go alongside its thermostable vaccine portfolio.